[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522009":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":39,"centralContacts":43,"locations":48,"responsibleParty":63,"collaborators":31,"id":66,"slug":31,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":31,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":31,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":31,"overallStatus":51,"whyStopped":31,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Vilanterol","EXPERIMENTAL","Participants inhale vilanterol + fluticasone furoat",[13],"Drug: Vilanterol and Fluticasone Furoate",{"label":15,"type":10,"description":16,"interventionNames":17},"Indacaterol","Participants inhale indacaterol + mometasone furoate",[18],"Drug: Indacaterol and Mometasone Furoate",{"label":20,"type":21,"description":22,"interventionNames":23},"Placebo","PLACEBO_COMPARATOR","Participants inhale placebo",[24],"Drug: Placebo",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Vilanterol and Fluticasone Furoate","Participants inhale 25 µg vilanterol + fluticasone furoate daily",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Indacaterol and Mometasone Furoate","Participants inhale 125 µg indacaterol + mometasone furoate daily",[15],{"type":27,"name":20,"description":37,"armGroupLabels":38,"otherNames":31},"Participants inhale placebo daily",[20],[40],{"name":41,"affiliation":5,"role":42},"Morten Hostrup, PhD","PRINCIPAL_INVESTIGATOR",[44],{"name":41,"role":45,"phone":46,"phoneExt":31,"email":47},"CONTACT","+4535321595","mhostrup@nexs.ku.dk",[49],{"facility":50,"status":51,"city":52,"state":31,"zip":53,"country":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"August Krogh Building","RECRUITING","Copenhagen","2100","Denmark",{"type":56,"coordinates":57},"Point",[58,59],12.56553,55.67594,{"lat":59,"lon":58},[62],{"name":41,"role":45,"phone":31,"phoneExt":31,"email":31},{"type":64,"investigatorFullName":41,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Associate Professor","100522009",false,"NCT06077019","Role of Lung Function for Exercise Capacity in Well-trained Individuals","Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals","Inclusion Criteria:\n\n* Age 18-39\n* Physically active \\> 5 h weekly\n* Maximal oxygen consumption classified as high or very high\n\nExclusion Criteria:\n\n* Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist\u002Fcorticosteroid\n* ECG abnormality\n* ACQ score \\> 1.5\n* Severe bronchial hyperreactivity as determined by mannitol test\n* FEV1\u002FFVC ratio \\\u003C 0.7 determined with spirometry\n* Chronic illness determined to be a potential risk for participant during study\n* In chronic treatment with medication that may interfere with study results\n* Pregnancy\n* Smoker\n* Blood donation during the past 3 months",true,"ALL","18 Years","39 Years",{"count":77,"type":78},60,"ESTIMATED","INTERVENTIONAL",[81],"NA","The purpose of the project is to investigate exercise performance in humans following prolonged inhalation of beta2-agonists vilanterol + fluticasone furoate or indacaterol + mometasone furoate",[84],"Exercise Performance","2025-04-07",{"date":87,"type":88},"2025-04-09","ACTUAL",{"date":90,"type":88},"2023-10-03",{"date":92,"type":78},"2026-12-01",{"name":41,"class":6},1]